NBIX
Price:
$120.17
Market Cap:
$12.13B
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a...[Read more]
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
1996-05-23
Stock Exchange
NASDAQ
Ticker
NBIX
According to Neurocrine Biosciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 12.29B. This represents a change of -6.66% compared to the average of 13.16B of the last 4 quarters.
The mean historical Enterprise Value of Neurocrine Biosciences, Inc. over the last ten years is 7.50B. The current 12.29B Enterprise Value has changed 16.28% with respect to the historical average. Over the past ten years (40 quarters), NBIX's Enterprise Value was at its highest in in the June 2024 quarter at 14.27B. The Enterprise Value was at its lowest in in the September 2014 quarter at 1.16B.
Average
7.50B
Median
7.61B
Minimum
1.64B
Maximum
13.05B
Discovering the peaks and valleys of Neurocrine Biosciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 187.81%
Maximum Annual Enterprise Value = 13.05B
Minimum Annual Increase = -30.58%
Minimum Annual Enterprise Value = 1.64B
Year | Enterprise Value | Change |
---|---|---|
2023 | 13.05B | 14.05% |
2022 | 11.44B | 40.28% |
2021 | 8.16B | -4.43% |
2020 | 8.53B | -16.59% |
2019 | 10.23B | 44.95% |
2018 | 7.06B | 1.69% |
2017 | 6.94B | 112.52% |
2016 | 3.27B | -30.58% |
2015 | 4.71B | 187.81% |
2014 | 1.64B | 182.34% |
The current Enterprise Value of Neurocrine Biosciences, Inc. (NBIX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
10.88B
5-year avg
10.28B
10-year avg
7.50B
Neurocrine Biosciences, Inc.’s Enterprise Value is greater than Amphastar Pharmaceuticals, Inc. (2.64B), greater than Collegium Pharmaceutical, Inc. (1.58B), greater than Ironwood Pharmaceuticals, Inc. (1.26B), greater than ANI Pharmaceuticals, Inc. (1.34B), greater than Deciphera Pharmaceuticals, Inc. (2.15B), greater than Alkermes plc (4.26B), greater than Avadel Pharmaceuticals plc (1.40B), greater than Intra-Cellular Therapies, Inc. (7.09B), greater than Dynavax Technologies Corporation (1.59B), greater than Pacira BioSciences, Inc. (1.04B), greater than Eagle Pharmaceuticals, Inc. (110.03M), greater than Prestige Consumer Healthcare Inc. (4.75B), greater than Evotec SE (1.33B), greater than Supernus Pharmaceuticals, Inc. (1.85B),
Company | Enterprise Value | Market cap |
---|---|---|
2.64B | $2.21B | |
1.58B | $1.20B | |
1.26B | $720.42M | |
1.34B | $1.27B | |
2.15B | $2.21B | |
4.26B | $4.42B | |
1.40B | $1.39B | |
7.09B | $7.77B | |
1.59B | $1.45B | |
1.04B | $638.86M | |
110.03M | $55.19M | |
4.75B | $3.68B | |
1.33B | $1.19B | |
1.85B | $1.86B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Neurocrine Biosciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Neurocrine Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Neurocrine Biosciences, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Neurocrine Biosciences, Inc. (NBIX)?
What is the 3-year average Enterprise Value for Neurocrine Biosciences, Inc. (NBIX)?
What is the 5-year average Enterprise Value for Neurocrine Biosciences, Inc. (NBIX)?
How does the current Enterprise Value for Neurocrine Biosciences, Inc. (NBIX) compare to its historical average?